TheraCoat snags $7M for bladder drug delivery platform; Echo wins IRB approval for Symphony glucose monitoring system;

> TheraCoat, the developer of a delivery platform that improves drug infiltration in the internal cavity of the bladder, welcomed a $7 million investment from Pontifax, CHealth Fund and private investors. More

> Echo Therapeutics ($ECTE) received IRB approval of a clinical trial of its Symphony CGM System, a noninvasive, wireless, transdermal continuous glucose monitoring system. Release

> TriStar Wellness Solutions signed a three-year licensing agreement with Polytherapeutics to use TriStar's PharmaDur drug-delivery technology to treat specific skin conditions and wounds. Release

> Sunovion Pharmaceuticals reported clinical trial results of its Brovana Inhalation Solution for serious respiratory events in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The results supported the long-term safety profile of the inhaled solution. Release

> BioRestorative Therapies signed a consulting agreement with Dexterity to advance production of BRT's delivery device for intervertebral disc stem cell therapy, brtxDISC. Release

 

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.